Eloxx Pharmaceuticals, Inc.
https://www.eloxxpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eloxx Pharmaceuticals, Inc.
Almirall Casts Its Net To Cover Butterfly Skin Disease
Deal Snapshot: The Spanish company is linking up with US biotech Eloxx to get hold of an asset that will be its first in the rare dermatological disease space.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Eloxx Limited
- Eloxx Pharmaceuticals, Ltd.
- Fabrus, Inc.
- Senesco Technologies, Inc.
- Sevion Therapeutics, Inc.
- Zikani Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice